Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/24/2025

Management of Sleep Disturbances in CKD Stage 5 on Twice-Weekly Hemodialysis

Introduction to Sleep Management

  • The American Journal of Kidney Diseases recommends that twice-weekly dialysis is only appropriate for patients with substantial residual kidney function (RKF), which is unlikely in CKD stage 5 5, 6
  • Increasing to three times weekly (minimum 3 hours per session) should be the immediate priority, as this addresses the root cause of uremic symptoms including sleep disorders 5, 7
  • Extended or more frequent hemodialysis (4-6 times weekly) may improve sleep quality, sleep apnea, and overall quality of life, though evidence certainty is low 1, 7

Systematic Symptom Assessment and Non-Pharmacologic Interventions

  • The Kidney International journal suggests using validated screening tools to quantify sleep disturbance and identify concurrent symptoms that may be contributing 1, 2, 4
  • The Edmonton Symptom Assessment System-revised: Renal (ESAS-r:R) is a 13-symptom tool rated 0-10 for severity 1, 4
  • The Pittsburgh Sleep Quality Index (PSQI) scores ≥5 indicate poor sleep quality (prevalence 65-83% in dialysis patients) 3
  • Cognitive behavioral therapy (CBT) has proven efficacy in reducing depression and may improve sleep in dialysis patients 1
  • Aerobic exercise decreases depressive symptoms and may improve sleep quality (moderate certainty evidence) 1, 4

Pharmacologic Management

  • The Kidney International journal recommends gabapentin as the preferred pharmacologic agent for sleep disorders in dialysis patients, with a dose of 100 mg post-dialysis or at bedtime, maximum 200-300 mg daily in ESRD 8, 9, 10
  • Ramelteon 8 mg at bedtime is an alternative pharmacologic option for refractory insomnia after optimizing dialysis and trying gabapentin 9
  • Zolpidem 5 mg requires dose adjustment and should be used cautiously 9
  • Long-acting benzodiazepines (e.g., flurazepam) should be avoided due to the risk of accumulation and cognitive impairment in uremic patients 9, 10

Addressing Concurrent Uremic Symptoms and Monitoring

  • The Kidney International journal suggests systematically managing coexisting symptoms that perpetuate insomnia, including uremic pruritus, depression, pain, and hyperphosphatemia 1, 2, 3
  • Reassess sleep quality at each dialysis visit using standardized tools, and evaluate medication efficacy and adverse effects (especially cognitive changes, falls) 1, 4, 8, 10
  • Escalate care urgently if sleep disturbance accompanies altered mental status or confusion, seizure activity, severe electrolyte abnormalities, volume overload refractory to current dialysis prescription, or progressive nutritional deterioration 10

REFERENCES

8

Management of Restless Legs Syndrome in Chronic Kidney Disease [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

9

Inductores del Sueño en Pacientes con EPOC y Falla Renal [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

10

Management of Jerky Movements in CKD Patients with Uremic Syndrome [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025